Advisors Asset Management’s Ascendis Pharma ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.13M Buy
9,352
+206
+2% +$52.2K 0.03% 608
2026
Q2
$2.44M Sell
9,146
-3,054
-25% -$713K 0.04% 554
2026
Q1
$2.79M Sell
12,200
-194
-2% -$43.5K 0.05% 496
2025
Q4
$2.64M Buy
12,394
+1,785
+17% +$369K 0.04% 513
2025
Q3
$2.11M Buy
10,609
+137
+1% +$25.6K 0.04% 584
2025
Q2
$1.81M Buy
10,472
+1,282
+14% +$209K 0.03% 593
2025
Q1
$1.43M Buy
9,190
+949
+12% +$136K 0.03% 654
2024
Q4
$1.13M Buy
8,241
+3,499
+74% +$460K 0.02% 713
2024
Q3
$708K Buy
4,742
+894
+23% +$121K 0.01% 824
2024
Q2
$525K Buy
+3,848
New +$524K 0.01% 879
2023
Q4
– Sell
-5,519
Closed -$517K – 1405
2023
Q3
$517K Sell
5,519
-98
-2% -$9.17K 0.01% 895
2023
Q2
$501K Sell
5,617
-270
-5% -$23.5K 0.01% 930
2023
Q1
$631K Sell
5,887
-254
-4% -$29.1K 0.01% 883
2022
Q4
$750K Sell
6,141
-9,675
-61% -$1.12M 0.02% 842
2022
Q3
$1.63M Sell
15,816
-933
-6% -$88.5K 0.03% 566
2022
Q2
$1.56M Sell
16,749
-22
-0.1% -$2.07K 0.03% 599
2022
Q1
$1.97M Buy
16,771
+520
+3% +$60.2K 0.03% 590
2021
Q4
$2.19M Buy
16,251
+1,443
+10% +$215K 0.03% 571
2021
Q3
$2.36M Sell
14,808
-212
-1% -$29K 0.04% 544
2021
Q2
$1.98M Buy
15,020
+1,240
+9% +$165K 0.03% 603
2021
Q1
$1.78M Buy
13,780
+5,267
+62% +$800K 0.03% 634
2020
Q4
$1.42M Buy
8,513
+3,916
+85% +$648K 0.02% 678
2020
Q3
$709K Buy
4,597
+560
+14% +$80.5K 0.01% 809
2020
Q2
$597K Buy
4,037
+2,693
+200% +$370K 0.01% 848
2020
Q1
$151K Buy
+1,344
New +$175K ﹤0.01% 1160

Other funds holding ASND

Advisors Asset Management's ASND Position: Q3 2026 in Review

Advisors Asset Management increased its Ascendis Pharma (ASND) stake by 2.3% in Q3 2026, buying an estimated $52.2K and bringing the position to 9,352 shares worth $2.13M. The position accounts for 0.03% of the portfolio, ranked #608.

Advisors Asset Management first reported a position in ASND in Q1 2020 and has held it in 25 quarters since. The position peaked at $2.79M in Q1 2026. 347 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

  • Advisors Asset Management held 9,352 shares of Ascendis Pharma worth $2.13M as of Q3 2026.
  • Advisors Asset Management bought 206 Ascendis Pharma shares in Q3 2026, an estimated $52.2K.
  • Ascendis Pharma made up 0.03% of Advisors Asset Management's portfolio in Q3 2026, its #608 holding.
  • Advisors Asset Management first reported a position in Ascendis Pharma in Q1 2020 and has held it in 25 quarters since.
  • Advisors Asset Management's Ascendis Pharma position peaked at $2.79M in Q1 2026.
  • 347 funds tracked by Wall St. Rank held Ascendis Pharma as of Q3 2026.

Based on Advisors Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.